SA author Regarded Solutions bangs the table for Achillion Pharmaceuticals (ACHN +5.1%), citing...


SA author Regarded Solutions bangs the table for Achillion Pharmaceuticals (ACHN +5.1%), citing its "wonderful balance sheet" and its four hepatitis C drugs, which could, "for all intents and purposes," cure the illness if approved. Achillion's promise has brought it several upgrades and made it a potential takeover target.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs